Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

By afschroeder • October 25, 2025

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov;26(7):e503-e513.e11. doi: 10.1016/j.cllc.2025.05.016. Epub 2025 Jun 6. PMID: 40582920.

Tags: ALK inhibitors, Cedars Sinai DoM, circulating tumor DNA, G1202R, Hematology/Oncology, Publications, Resistance mutations, Tumor biopsy

Response

Matusov Y, Kolaitis NA, Geft D, DesJardin J, Barnett C, Hage A, De Marco T, Lewis MI. Response. Chest. 2026 Mar;169(3):e120. doi: 10.1016/j.chest.2025.10.024. PMID: 41813311.

Stress Trajectory and Hypertension 2 to 7 Years After Delivery: A nuMoM2b-HHS Study

Nuckols VR, Barone Gibbs B, Brewer BC, Gaffey AE, Greaney JL, Patterson F, Greenland P, Saade GR, Grobman WA, Yee LM, Bairey Merz CN, Chung[...]

Dietary Intake of Macronutrients and Micronutrients in Women with Functional Hypothalamic Amenorrhea

Uddenberg ER, Safwan N, Castaneda R, Saadedine M, Maughan J, Hurtado Andrade MD, Faubion SS, Pisarska MD, Berga SL, Manson JE, Merz CNB, Shufelt CL.[...]